A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer

BACKGROUND: In this open-label phase I study, the maximum-tolerated dose of cetuximab with concurrent chemoradiotherapy (C-CRT) in stage III non–small-cell lung cancer together with individualized, isotoxic accelerated radiotherapy (RT) was investigated. METHODS: Patients with stage III non–small-ce...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dingemans, Anne-Marie C., Bootsma, Gerben, van Baardwijk, Angela, Reymen, Bart, Wanders, Rinus, Brans, Boudewijn, Das, Marco, Hochstenbag, Monique, van Belle, Arne, Houben, Ruud, Lambin, Philippe, de Ruysscher, Dirk
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2014
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4132032/
https://ncbi.nlm.nih.gov/pubmed/24722157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000151
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares